Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-26
2006-09-26
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S269000, C544S122000, C544S296000, C544S298000
Reexamination Certificate
active
07112585
ABSTRACT:
The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”)useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
REFERENCES:
patent: WO 95/10506 (1995-04-01), None
patent: WO 95/33750 (1995-12-01), None
patent: WO 97/45421 (1997-12-01), None
patent: WO 98/03510 (1998-01-01), None
patent: WO 99/51608 (1999-10-01), None
patent: WO 00/53604 (2000-09-01), None
patent: WO 00/59888 (2000-10-01), None
patent: WO 01/53263 (2001-07-01), None
patent: WO 01/62718 (2001-08-01), None
patent: WO 01/68614 (2001-09-01), None
patent: WO 02/06242 (2002-01-01), None
Ulrich, Crystallization, Kirk-Othmer Encyclopedia of Chemical Technology, vol. 8, pp. 113-120, (http://www.mrw.interscience.wiley.com/kirk/articles/crysrous.a01/sect4-fs.html) Aug. 2002.
West, Solid Solutions, Solid state chemistry and it's applications, Wiley, New York, pp. 358 and 365, 1988.
Vippagunta et al., Crystalline solids, Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26, 2001.
Dunn, A.J., et al., “Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?” Brain Research Reviews, 15, 1990, pp. 71-100.
Gulyas, J, et al., “Potent structurally constrained agonists and competitive antagonists of corticotropin-releasing factor,” Proc. Natl. Acad. Sci. USA, vol. 92, Nov. 1995, pp. 10575-10579.
McCarthy, et al., “Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications,” Current Pharmaceutical Design, 1999, 5, pp. 289-315.
Holsboer, F., “The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety,” Journal of Psychiatric Research, 33, 1999, pp. 181-214.
Banki, C.M., et al., “CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse,” European Neuropsychopharmacology, 2, 1992, pp. 107-113.
Webster, E.L., et al., “Corticotropin-Releasing Hormone and Inflammation,” Annals New York Academy of Sciences, 840, 1998, pp. 21-32.
Gilligan, P.J., et al., “Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents,” Journal of Medicinal Chemistry, vol. 43, No. 9, May 4, 2000, pp. 1641-1660.
McCarthy, J.R., et al., “Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents,” Annual Reports in Medicinal Chemistry, vol. 34, 1999, pp. 11-20.
Arvanitis Argyrios G.
Hartz Richard A.
Bristol--Myers Squibb Company
Epperson James R.
Makujina Shah R.
Rao Deepak
LandOfFree
Pyrimidine derivatives as corticotropin releasing factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivatives as corticotropin releasing factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives as corticotropin releasing factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3525991